These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33916226)

  • 1. Telemedicine Chronic Viral Hepatitis C Treatment during the Lockdown Period in Romania: A Pilot Study.
    Doica IP; Florescu DN; Oancea CN; Turcu-Stiolica A; Subtirelu MS; Dumitra G; Rogoveanu I; Gheonea DI; Ungureanu BS
    Int J Environ Res Public Health; 2021 Apr; 18(7):. PubMed ID: 33916226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing Telemedicine and Modified Fibrosis Staging Protocols to Maintain Treatment Initiation and Adherence Among Hepatitis C Patients During the COVID-19 Pandemic.
    O'Brien M; Daws R; Amin P; Lee K
    J Prim Care Community Health; 2022; 13():21501319221108000. PubMed ID: 35748428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C).
    Talal AH; Markatou M; Sofikitou EM; Brown LS; Perumalswami P; Dinani A; Tobin JN
    Contemp Clin Trials; 2022 Jan; 112():106632. PubMed ID: 34813962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic.
    Hartl L; Jachs M; Bauer D; Simbrunner B; Chromy D; Binter T; Steininger L; Schwarz C; Schwarz M; Burghart L; Strassl R; Trauner M; Gschwantler M; Mandorfer M; Reiberger T
    J Viral Hepat; 2022 Dec; 29(12):1062-1072. PubMed ID: 36062398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy.
    Cooper MP; Foley H; Damico D; Wright M; Rhudy C; Schadler A; Platt T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):667-672. PubMed ID: 35621721
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic viral hepatitis C micro-elimination program using telemedicine in Guigang city.
    Lv R; Lu Y; Xiang W; Meng M; Li S
    J Viral Hepat; 2024 Apr; 31(4):208-215. PubMed ID: 38326936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
    Mennini FS; Marcellusi A; Robbins Scott S; Montilla S; Craxi A; Buti M; Gheorghe L; Ryder S; Kondili LA
    Liver Int; 2021 May; 41(5):934-948. PubMed ID: 33529499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience.
    Pérez Hernández JL; Higuera de la Tijera MF; Arce Salinas CA
    Rev Esp Enferm Dig; 2021 Aug; 113(8):624-625. PubMed ID: 33569965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients.
    Cooper CL; Hatashita H; Corsi DJ; Parmar P; Corrin R; Garber G
    Ann Hepatol; 2017 November-December,; 16(6):874-880. PubMed ID: 29055923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the "peer tele-HCV" study.
    Herink MC; Seaman A; Leichtling G; Larsen JE; Gailey T; Cook R; Thomas A; Korthuis PT
    Addict Sci Clin Pract; 2023 May; 18(1):35. PubMed ID: 37245041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience.
    Pérez Hernández JL; Lehmann Mendoza R; Luna Martínez J; Torres Roldán JF; Chaidez Rosales PA; Martinez Arredondo HA; Rebollar González V; De la Cruz Silva L; Santana Vargas D; Higuera de la Tijera MF; Arce Salinas CA
    Rev Esp Enferm Dig; 2021 Jun; 113(6):432-435. PubMed ID: 33267593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital.
    Frye K; Davis A; Darby R; McDaniel K; Quairoli K; Liu Z; Miller LS; Fluker SA
    J Viral Hepat; 2024 Apr; 31(4):176-180. PubMed ID: 38369695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
    Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
    Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
    Gheorghe L; Preda C; Trifan A; Manuc M; Stanciu C; Istratescu D; Popescu CP; Diculescu MM; Tieranu CG; Manuc T; Stroie TG; Iacob SM; Iliescu L
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):437-443. PubMed ID: 36535062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of COVID-19 on the cascade of care of HCV in the US and China.
    Yeo YH; Gao X; Wang J; Li Q; Su X; Geng Y; Huang R; Wu C; Ji F; Sundaram V; Noureddin M; Buti M; Ayoub WS
    Ann Hepatol; 2022; 27(3):100685. PubMed ID: 35192964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
    Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
    Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
    Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
    JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
    Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
    Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.